Standard BioTools Inc. Proceeds from Lines of Credit
Standard BioTools Inc. (LAB) reported Proceeds from Lines of Credit of $0 for the 12-month period ending 2015-12-31, per its 10-K filed 2016-02-29.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2016-02-29
- Standard BioTools Inc. proceeds from lines of credit for the quarter ending 2013-12-31 was $0.00.
- Standard BioTools Inc. proceeds from lines of credit for the quarter ending 2013-09-30 was $0.00.
- Standard BioTools Inc. proceeds from lines of credit for the quarter ending 2012-12-31 was $0.00.
- Standard BioTools Inc. proceeds from lines of credit for the quarter ending 2012-09-30 was $0.00.
- Standard BioTools Inc. proceeds from lines of credit for fiscal 2015 was $0.00.
- Standard BioTools Inc. proceeds from lines of credit for fiscal 2014 was $0.00.
- Standard BioTools Inc. proceeds from lines of credit for fiscal 2013 was $0.00, a 100.00% decline from fiscal 2012.
- Standard BioTools Inc. proceeds from lines of credit for fiscal 2012 was $1.88M.
| Period end | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month |
|---|---|---|---|---|
| 2015-12-31 | $0.00 10-K · filed 2016-02-29 | |||
| 2014-12-31 | $0.00 10-K · filed 2016-02-29 | |||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $0.00 derived: sum of 2 quarters · filed 2016-02-29 | $0.00 10-K · filed 2016-02-29 | |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $0.00 10-Q · filed 2013-11-07 | ||
| 2013-06-30 | $0.00 10-Q · filed 2013-08-07 | |||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $0.00 derived: sum of 2 quarters · filed 2015-02-26 | $1.88M 10-K · filed 2015-02-26 | |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $1.88M 10-Q · filed 2013-11-07 | ||
| 2012-06-30 | $1.88M 10-Q · filed 2013-08-07 | |||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-12 | $0.00 derived: sum of 2 quarters · filed 2014-03-12 | $0.00 10-K · filed 2014-03-12 | |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $0.00 10-Q · filed 2012-11-09 | ||
| 2011-06-30 | $0.00 10-Q · filed 2012-08-14 | |||
| 2010-12-31 | $3.13M 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |